Editorial
Copyright ©The Author(s) 2021.
World J Gastroenterol. Apr 21, 2021; 27(15): 1524-1530
Published online Apr 21, 2021. doi: 10.3748/wjg.v27.i15.1524
Table 1 Existing literature around textbook outcome in hepatopancreatobiliary surgery
Ref.Study periodDatabaseIndicationComponents of TOTO rates
Merath et al[3], 20192013-2015MedicareBenign and malignant hepatopancreatic lesionsNo complications. No prolonged LOS. No 90-d mortality. No 90-d readmission44.0%
Merath et al[4], 20201993-2015Multi-institutional ICC databaseIntrahepatic cholangiocarcinomaR0 resection No transfusion. No complications. No prolonged LOS. No 30-d mortality. No 30-d readmission25.5%
Tsilimigras et al[5], 20202000-2015Multi-institutional HCC databaseHepatocellular carcinomaR0 resection No reoperation. No complications (Clavien-Dindo ≥ III) No prolonged LOS. No 90-d mortality. No 90-d readmission62.3%
Heidsma et al[15], 20202000-2016US Neuroendocrine Tumor Study Group databasePancreatic neuroendocrine tumorsR0 resection No complications (Clavien-Dindo ≥ III). No prolonged LOS. No 90-d mortality. No 90-d readmission49.3%